9/3/2009

TEST QUESTIONS/ ANSWERS – EPRC BIOLOGICAL AGENTS

Q13. What CBRNE agents are living organisms, or materials derived from
them, that cause disease or harm to humans, animals, or plants?

A. Chemical
B. Biological
C. Radiological
D. Nuclear
E. Explosives

Q14. A mysterious illness has appeared in Bedford, Texas. An unidentified

single-celled organism that multiplies by cell division has been identified in all
victims. Which of the following does this characteristic identify?

A. Bacterial infection
B. Viral encephalitis effects
C. T-2 mycotoxin infection
D. Ionizing radiation effects

Q16. Petty Officer Rodriquez has been admitted to the emergency department.
The following symptoms have been identified: fever, nausea, vomiting,
abdominal pain, diarrhea, and buboes. Based on symptoms, which diagnosis
do you support?

A. Encephalitis
B. Plague
C. Anthrax

Q20. Experts anticipate that biological terrorist attacks are ________________.

A. the most likely to occur, and will have the greatest impact on the greatest
number of people.
B. likely to have limited use due to the rapid onset of symptoms
C. not likely to occur since the agent is too expensive for most terrorist groups to
obtain and pose little threat for areas with a great number of people.
D. not likely to occur due to the high cost of obtaining doses effective enough to
impact a great number of people

Q23. An outbreak has hit the community. The only noticeable pattern so far is
that the first patients own outdoor dogs and cats which have died. It is
suspected that fleas delivered the disease to their owners. What type of
CBRNE agent may have been used?

A. Chemical
B. Biological
C. Radiological

1
9/3/2009

Q61. What clinical form of Anthrax is NOT contracted by exposure to infected

animals?

A. Gastrointestinal
B. Cutaneous
C. Inhalational
D. Septicemic

Q62. What type of agent makes up a large part of a terrorist threat and can be
manufactured or modified to increase their virulent characteristics and are
effectively dispersed as aerosols?

A. Chemical
B. Bacterial
C. Vesicant
D. Pulmonary

Q63. A patient was admitted to the hospital suffering from the following
symptoms for the last 5 days: fever, malaise, fatigue, and nonproductive
cough. Chest x-rays reveal a widened mediastinum and the patient’s white
blood cell count is elevateD. Which type of anthrax is responsible for the
patient’s symptoms?

A. Inhalational
B. Cutaneous
C. Gastrointestinal
D. Septicemic

Q64. The definitive means of confirming a diagnosis of tularemia is the growth

of ______________ in cultures.

A. Yersinia pestis
B. Bacillus anthracis
C. Brucellae suis
D. Francisella tularensis

Q65. Smallpox can spread from one person to another by the following routes:

A. Aerosols generated by a patient sneezing or coughing

B. Droplets during face-to-face contact with a patient
C. Direct contact with the patient’s scabs
D. All answers are correct

Q66. Which of the following factors is NOT associated with Venezuelan Equine
Encephalitis (VEE)?

A. Endemic in northern South America to Mexico (and Florida)

B. Direct person-to-person spread has not been documented
C. May cause 10% mortality in adults and 30% case in children
D. Specific antiviral therapy is available

2
9/3/2009

Q67. What class of biological agent is produced and derived from living
plants, animals, or some microorganisms?

A. Viral
B. Bacteria
C. Toxins
D. None of the above

Q68. Processed foods and temperature-abused foods are most commonly

associated with ________ poisoning.

A. Ricin
B. T-2 Mycotoxins
C. Botulinum Neurotoxin
D. Staphylococcal Enterotoxin B (SEB)

Q69. What treatment should be given to a patient exposed to T-2 mycotoxins

via ingestion?

A. Only supportive care is needed.

B. Decontaminate patient and give antitoxin injections.
C. Supportive care and provide respiratory support.
D. Therapy for poison ingestion including the use of charcoal.

Q70. Which biological toxin acts by inhibiting DNA replication and protein
synthesis?

A. T-2 Mycotoxins
B. Ricin
C. Botulinum Neurotoxin
D. Staphylococcal Enterotoxin B